Stock Analysis on Net
Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Total Asset Turnover 
since 2012

Microsoft Excel

Calculation

AbbVie Inc., total asset turnover, long-term trends, calculation

Microsoft Excel
Total asset turnover = Net revenues1 ÷ Total assets1
Dec 31, 2025 0.46 = 61,160 ÷ 133,960
Dec 31, 2024 0.42 = 56,334 ÷ 135,161
Dec 31, 2023 0.40 = 54,318 ÷ 134,711
Dec 31, 2022 0.42 = 58,054 ÷ 138,805
Dec 31, 2021 0.38 = 56,197 ÷ 146,529
Dec 31, 2020 0.30 = 45,804 ÷ 150,565
Dec 31, 2019 0.37 = 33,266 ÷ 89,115
Dec 31, 2018 0.55 = 32,753 ÷ 59,352
Dec 31, 2017 0.40 = 28,216 ÷ 70,786
Dec 31, 2016 0.39 = 25,638 ÷ 66,099
Dec 31, 2015 0.43 = 22,859 ÷ 53,050
Dec 31, 2014 0.72 = 19,960 ÷ 27,547
Dec 31, 2013 0.64 = 18,790 ÷ 29,198
Dec 31, 2012 0.68 = 18,380 ÷ 27,008

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).

1 US$ in millions

The total asset turnover ratio for the period examined demonstrates considerable fluctuation. Initially, the ratio exhibited a moderate decline from 0.68 in 2012 to 0.64 in 2013, followed by a slight recovery to 0.72 in 2014. A significant decrease was then observed, falling to 0.43 in 2015 and continuing to 0.39 in 2016. The ratio experienced a modest increase to 0.40 in 2017 before declining again to 0.37 in 2019. A subsequent rise to 0.38 in 2020 was followed by a further increase to 0.42 in 2021 and remained at 0.40 in 2022. The most recent years show a slight upward trend, reaching 0.42 in 2023 and 0.46 in 2025.

Overall Trend
The overall trend indicates a generally lower asset turnover compared to the earlier years of the period. While fluctuations occur, the ratio generally remains below the initial levels observed in 2012 and 2013. The recent increase suggests a potential stabilization or improvement in asset utilization.
Significant Declines
The most substantial declines in the ratio occurred between 2014 and 2016, coinciding with a significant increase in total assets. This suggests that asset growth outpaced revenue growth during this period, leading to reduced efficiency in asset utilization. The decline from 2018 to 2019 also warrants attention, potentially indicating a temporary slowdown in revenue generation relative to the asset base.
Recent Performance
The ratio’s performance from 2021 to 2025 shows a slight improvement, moving from 0.38 to 0.46. This suggests that the company is becoming more efficient in generating revenue from its assets, although it has not yet returned to the levels seen in the early part of the analyzed period. The increase in 2025 is the highest observed in the last decade.
Relationship to Revenue and Assets
The fluctuations in the total asset turnover ratio appear closely linked to changes in both net revenues and total assets. Periods of substantial asset growth, particularly between 2015 and 2020, often correlate with lower turnover ratios. Conversely, periods where revenue growth outpaces asset growth, such as between 2020 and 2022, tend to result in higher ratios.

AI Ask an analyst for more

Comparison to Competitors

AbbVie Inc., total asset turnover, long-term trends, comparison to competitors

Microsoft Excel
AbbVie Inc. Amgen Inc. Bristol-Myers Squibb Co. Danaher Corp. Eli Lilly & Co. Gilead Sciences Inc. Johnson & Johnson Merck & Co. Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Vertex Pharmaceuticals Inc.
Dec 31, 2025 0.46 0.39 0.54 0.29 0.58 0.49 0.47 0.47 0.30 0.35 0.40 0.47
Dec 31, 2024 0.42 0.35 0.52 0.31 0.57 0.48 0.49 0.55 0.30 0.38 0.44 0.49
Dec 31, 2023 0.40 0.28 0.47 0.28 0.53 0.43 0.51 0.56 0.26 0.40 0.43 0.43
Dec 31, 2022 0.42 0.38 0.48 0.37 0.58 0.43 0.51 0.54 0.51 0.42 0.46 0.49
Dec 31, 2021 0.38 0.40 0.42 0.35 0.58 0.40 0.52 0.46 0.45 0.63 0.41 0.56
Dec 31, 2020 0.30 0.39 0.36 0.29 0.53 0.36 0.47 0.52 0.28 0.50 0.47 0.53
Dec 31, 2019 0.37 0.37 0.20 0.29 0.57 0.36 0.52 0.55 0.31 0.53 0.44 0.50
Dec 31, 2018 0.55 0.34 0.64 0.42 0.56 0.34 0.53 0.51 0.34 0.57 0.43 0.49
Dec 31, 2017 0.40 0.27 0.62 0.39 0.51 0.37 0.49 0.46 0.31 0.67 0.37 0.70
Dec 31, 2016 0.39 0.28 0.58 0.37 0.55 0.53 0.51 0.42 0.31 0.70 0.40 0.59
Dec 31, 2015 0.43 0.29 0.52 0.43 0.56 0.62 0.53 0.39 0.29 0.73 0.41 0.41
Dec 31, 2014 0.72 0.28 0.47 0.54 0.53 0.71 0.57 0.43 0.29 0.73 0.39 0.25
Dec 31, 2013 0.64 0.28 0.42 0.55 0.66 0.48 0.54 0.42 0.30 0.71 0.41 0.52
Dec 31, 2012 0.68 0.31 0.49 0.55 0.66 0.44 0.55 0.45 0.32 0.66 0.46 0.55

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).

Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

AbbVie Inc., total asset turnover, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel
AbbVie Inc. Pharmaceuticals, Biotechnology & Life Sciences
Dec 31, 2025 0.46 0.43
Dec 31, 2024 0.42 0.43
Dec 31, 2023 0.40 0.40
Dec 31, 2022 0.42 0.47
Dec 31, 2021 0.38 0.45
Dec 31, 2020 0.30 0.39
Dec 31, 2019 0.37 0.39
Dec 31, 2018 0.55 0.45
Dec 31, 2017 0.40 0.40
Dec 31, 2016 0.39 0.41
Dec 31, 2015 0.43 0.42
Dec 31, 2014 0.72 0.44
Dec 31, 2013 0.64 0.43
Dec 31, 2012 0.68 0.45

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).

Comparison to Industry (Health Care)

AbbVie Inc., total asset turnover, long-term trends, comparison to industry (health care)

Microsoft Excel
AbbVie Inc. Health Care
Dec 31, 2025 0.46 0.67
Dec 31, 2024 0.42 0.65
Dec 31, 2023 0.40 0.63
Dec 31, 2022 0.42 0.66
Dec 31, 2021 0.38 0.62
Dec 31, 2020 0.30 0.57
Dec 31, 2019 0.37 0.57
Dec 31, 2018 0.55 0.63
Dec 31, 2017 0.40 0.56
Dec 31, 2016 0.39 0.57
Dec 31, 2015 0.43 0.55
Dec 31, 2014 0.72 0.60
Dec 31, 2013 0.64 0.58
Dec 31, 2012 0.68 0.58

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).